Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...

Sales of Keytruda from Merck reached $25 billion last year thanks to its position as a standard first line of treatment for ...

Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine. Moderna's ...

These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing ...

Overview of the Current Covid-19 Situation in Israel The Covid-19 vaccination program in Israel is progressing at a fast pace ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Evercore ISI upgraded Sprouts Farmers Market (SFM) to Outperform from In Line with a price target of $120, up from $96. The ...

Drones are set to play a vital role in the clinical supply chain across sub-Saharan Africa. How are these new logistical ...

The UK has approved its second Covid-19 vaccine for emergency use: AZ/Oxford’s candidate. This is welcome news given how ...

Fidelity Advisor Equity Growth Fund 305.17k Jul 31, 2024 0.13% 729,349,130 ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

Jefferies upgraded BioNTech (BNTX) to Buy from Hold with a price target of $150, up from $96. Following Summit Therapeutics' ...